Use of neuromuscular blocking drugs in intensive care unit patients.
Miller
R D
RD
D001279:Atracurium / Q000008:administration & dosage; D002648:Child; D003422:Critical Care; D017277:Drug Approval; D006801:Humans; D008991:Monitoring, Physiologic; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010197:Pancuronium / Q000008:administration & dosage; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012121:Respiration, Artificial; D013237:Stereoisomerism; D014481:United States; D014486:United States Food and Drug Administration; D014673:Vecuronium Bromide / Q000008:administration & dosage
D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D014673:Vecuronium Bromide; D010197:Pancuronium